The effect of vitamin D supplementation in treatment of endometriosis

Study of the effect of vitamin D supplementation on clinical symptoms, parameters of mental health, metabolic profiles, inflammatory factors and biomarkers of oxidative stress in patients with endometriosis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N60

Enrollment

Registered

2019-06-15

Start date

2019-04-08

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis. Endometriosis

Interventions

Intervention 1: Intervention group: 50000 IU vitamin D biweekly (Zahravi, Tabriz, Iran), for 12 weeks orally. Intervention 2: Control group: vitamin D placebo (Barij essence, Kashan, Iran), every 2 w

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: women with endometriosis Individuals aged 18-40

Exclusion criteria

Exclusion criteria: Diabetes mellitus Thyroid disorders Hypertension Hyperprolactinemia Cushing syndrome

Design outcomes

Primary

Measure	Time frame
Malondialdehyde. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.	—

Secondary

Measure	Time frame
Dyspareunia. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Dysmenorrhea. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Dysuria. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Pelvic pain. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Beck depression questionnaire. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;General health questionnaire. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.	—

Measure

Time frame

Dyspareunia. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Dysmenorrhea. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Dysuria. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Pelvic pain. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Glutathione. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Beck depression questionnaire. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;General health questionnaire. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire.;Hs-CRP. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026